Byers et al. (2022) reported results of a phase 1 trial of CAR-T cells directed against DLL3 in patients with relapsed or refractory small cell lung cancer and found a possible signal of efficacy and no concerning safety signals [39]. Here, DLL3 is linked to small cell lung carcinoma.